Neuroendocrine tumors (NETs) are heterogeneous malignancies arising from the diffuse
neuroendocrine system. They frequently originate in the gastroenteropancreatic (GEP) tract …

Nuclear medicine plays an increasingly important role in the management neuroendocrine
neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission …

Background The primary analysis of the phase 3 NETTER-1 trial showed significant
improvement in progression-free survival with 177 Lu-Dotatate plus long-acting octreotide …

As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT),
Lutathera® was approved by the EMA in 2017 and the FDA in 2018 for the treatment of …

Only advances that occurred from 2011 to 2014 that either strengthen the previous 2011
guidelines [1, 2] or lead to changes or additional guidelines are reviewed here. Advances …

Cancer became recently the leading cause of death in industrialized countries. Even though
standard treatments achieve significant effects in growth inhibition and tumor elimination …

Ectopic ACTH syndrome (EAS) is rare but is frequently a severe condition because of the
intensity of the hypercortisolism that may be dissociated from the tumoral condition. EAS …

Peptide receptor radionuclide therapy (PRRNT) is a molecularly targeted radiation therapy
involving the systemic administration of a radiolabelled peptide designed to target with high …

Purpose Peptide receptor radionuclide therapy (PRRT) with 90 Y and 177 Lu provides
objective responses in neuroendocrine tumours, and is well tolerated with moderate toxicity …

In the United States,[68Ga] Ga-DOTA-TOC has been approved by the Food and Drug
Administration (FDA) in 2019 as the first 68Ga-radiopharmaceutical for imaging of …